Skip to main content
. 2013 Oct 9;8(10):e77277. doi: 10.1371/journal.pone.0077277

Figure 2. Endothelial extracellular matrix (ECM) transglutaminase 2 (TG2) activity analyses by monodansylcadaverine (MDC) incorporation.

Figure 2

(A) The relative ECM-TG2 activity at different time points by ELISA. The dashed line indicates TG2 activity in untreated endothelial cells (HUVEC). Bars represent mean MDC incorporation as fold of control and error bars indicate standard error of the mean. P-value < 0.05 was considered significant ( **p<0.001 and *p<0.01). Data derived from three independent experiments, repeated in quadruplicate. (B) Western blotting analyses of endothelial ECM-TG2 activity measured by the incorporation of MDC. Endothelial cells were treated with celiac disease patient (CD IgA) and non-celiac subject’s immunoglobulin-A (H IgA). Extracellular TG2 activity was inhibited by administering a non-permeable, site directed TG2 inhibitor, R281.